Aardvark Therapeutics, Inc.
AARD Nasdaq
SEC CIK 1774857
Follow Aardvark Therapeutics
Weekly email: filings, results
Revenue, last quarter
$0
Net income
−$19.2M
−17.6% vs same quarter last year
EPS, diluted
−$0.88
−17.3% vs same quarter last year
Operating cash flow
−$13.5M
+16.1% vs same quarter last year
Source: SEC XBRL filings · latest filing